申请人:UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
公开号:US10973766B2
公开(公告)日:2021-04-13
The invention relates to an oral polymeric pharmaceutical dosage form which comprises a thermoresponsive eutectic composition which is solid at or about room temperature and fluid at or about body temperature, the eutectic composition mixed together with a crosslinking agent and an active pharmaceutical ingredient (API) to form an API loaded region; and a porous polymeric composition at least partially surrounding the API loaded region to protect the API when the dosage form is in a stomach of the human or animal body, the porous polymeric composition allowing the ingress of water to contact the crosslinking agent thereby facilitating the crosslinking agent to cause crosslinking of the porous polymeric composition, which crosslinked porous polymeric composition allows controlled egress of API via egress of fluid thermoresponsive eutectic composition at the intestine. In a preferred embodiment, the dosage form further comprises a coating there around.
本发明涉及一种口服聚合药物剂型,它包括一种热致共晶组合物,该组合物在室温或室温左右为固体,在体温或体温左右为流体,该共晶组合物与交联剂和活性药物成分(API)混合在一起,形成一个API负载区;多孔聚合物组合物至少部分地围绕着装载 API 的区域,以便在剂型处于人体或动物胃中时保护 API,多孔聚合物组合物允许水进入接触交联剂,从而促进交联剂引起多孔聚合物组合物的交联,交联后的多孔聚合物组合物允许通过流体热共晶组合物在肠道的流出控制 API 的流出。在一个优选的实施方案中,该剂型还包括一层涂层。